EyePoint Pharmaceuticals, Inc. Banner Image

EyePoint Pharmaceuticals, Inc. has reached its limit for free report views

Work for EyePoint Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

EyePoint Pharmaceuticals, Inc.

  • Ticker EYPT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
EyePoint Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Watertown, Massachusetts
EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment ofMore postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF therapy initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey.
EyePoint Pharmaceuticals, Inc.

Most Recent Annual Report

EyePoint Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. EyePoint Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports